Histogenics Corporation (HSGX) Analysts See $-0.31 EPS

February 24, 2018 - By Linda Rogers

 Histogenics Corporation (HSGX) Analysts See $ 0.31 EPS

Analysts expect Histogenics Corporation (NASDAQ:HSGX) to report $-0.31 EPS on March, 15.They anticipate $1.29 EPS change or 80.63 % from last quarter’s $-1.6 EPS. After having $-0.23 EPS previously, Histogenics Corporation’s analysts see 34.78 % EPS growth. It closed at $2.59 lastly. It is down 7.61% since February 24, 2017 and is downtrending. It has underperformed by 24.31% the S&P500.

Histogenics Corporation (NASDAQ:HSGX) Ratings Coverage

Among 6 analysts covering Histogenics Corp (NASDAQ:HSGX), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Histogenics Corp had 16 analyst reports since August 27, 2015 according to SRatingsIntel. The rating was maintained by Needham on Friday, November 13 with “Buy”. H.C. Wainwright maintained the shares of HSGX in report on Thursday, November 2 with “Buy” rating. As per Thursday, December 21, the company rating was maintained by Canaccord Genuity. Zacks downgraded Histogenics Corporation (NASDAQ:HSGX) on Thursday, August 27 to “Hold” rating. The firm has “Buy” rating given on Monday, October 16 by Canaccord Genuity. Needham maintained the stock with “Buy” rating in Monday, September 19 report. The rating was maintained by H.C. Wainwright on Wednesday, December 27 with “Buy”. The firm has “Buy” rating by H.C. Wainwright given on Monday, December 19. The firm earned “Buy” rating on Friday, August 12 by BTIG Research. The stock has “Buy” rating by Canaccord Genuity on Friday, November 13.

Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company has market cap of $63.64 million. The firm offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It currently has negative earnings. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans.

More notable recent Histogenics Corporation (NASDAQ:HSGX) news were published by: Globenewswire.com which released: “Histogenics Corporation Announces Closing of Underwritten Registered Direct …” on January 25, 2018, also Globenewswire.com with their article: “Histogenics Corporation to Present at the 2017 Cell & Gene Meeting on the Mesa” published on September 26, 2017, Globenewswire.com published: “Histogenics Corporation Announces Pricing of Underwritten Registered Direct …” on January 22, 2018. More interesting news about Histogenics Corporation (NASDAQ:HSGX) were released by: Globenewswire.com and their article: “Histogenics Corporation Promotes Stephen Kennedy to Executive Vice President …” published on October 12, 2017 as well as Globenewswire.com‘s news article titled: “Histogenics Corporation Announces Third Quarter 2017 Financial and Operating …” with publication date: November 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: